Mediators of Inflammation / 2020 / Article / Tab 2

Research Article

New Potential Weapons for Refractory Scleritis in the Era of Targeted Therapy

Table 2

Clinical characteristics and past treatments of 14 patients enrolled.

PatientAge/sexAnatomical patternLateralitySystemic diseasePreceding biologics and their dose

142/MNodular ASBilateralGPA
276/MNecrotizing ASUnilateralMPA
366/MDiffuse ASUnilateralRA
416/FPosterior scleritisUnilateralIdiopathic
532/FDiffuse ASUnilateralGPA
656/FDiffuse ASBilateralRAADA (40 mg/2 weeks), ABA (125 mg/week), IFX (5 mg/kg/4 weeks)
746/MDiffuse ASUnilateralPsAADA 40 mg/2 weeks, IFX (5 mg/kg/4 weeks)
818/FPosterior scleritisUnilateralIdiopathicRTX (2 gr/6 months)
959/MNodular ASBilateralRA
1066/MPosterior scleritisUnilateralFMF
1154/FDiffuse ASBilateralRAADA (40 mg/2 weeks)
1252/FDiffuse ASUnilateralRA
1334/FDiffuse ASUnilateralRA
1445/FDiffuse ASBilateralRAETN (50 mg/week), ADA (40 mg/2 weeks), TCZ (162 mg/week), RTX (2 gr/6 months)

ABA: abatacept; ADA: adalimumab; AS: anterior scleritis; F: female; GPA: granulomatosis with polyangiitis; IFX: infliximab; M: male; MPA: microscopic polyangiitis; PsA: psoriatic arthritis; RA: rheumatoid arthritis; RTX: rituximab; TCZ: tocilizumab.

Article of the Year Award: Outstanding research contributions of 2020, as selected by our Chief Editors. Read the winning articles.